BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 1891177)

  • 21. Pharmacokinetics of chlorambucil in patients with chronic lymphocytic leukaemia: comparison of different days, cycles and doses.
    Silvennoinen R; Malminiemi K; Malminiemi O; Seppälä E; Vilpo J
    Pharmacol Toxicol; 2000 Nov; 87(5):223-8. PubMed ID: 11129502
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cytotoxicity and metabolism of prednimustine, chlorambucil and prednisolone in a Chinese hamster cell line.
    Hartley-Asp B; Gunnarsson PO; Liljekvist J
    Cancer Chemother Pharmacol; 1986; 16(2):85-90. PubMed ID: 3948307
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical trial of prednimustine, Leo-1031 (NSC-134087), in patients with non-Hodgkin lymphomata and chronic lymphocytic leukaemia previously treated with steroids and alkylating agents.
    Pedersen-Bjergaard J; Hansen MM; Geisler CH; Nissen NI
    Acta Med Scand; 1980; 207(3):215-20. PubMed ID: 6989170
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Some metabolic aspects of a nitrogen mustard of prednisolone.
    Kirdani RY; Murphy GP; Sandberg AA
    Oncology; 1978; 35(2):47-53. PubMed ID: 652263
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Value of prednimustine in treating non Hodgkin's lymphomas of favourable histological type.
    Klener P; Háber J
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1985; 112(1):103-8. PubMed ID: 2581855
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chemotherapy in metastatic, hormone refractory prostatic cancer using chlorambucil in combination with prednisolone versus conjugate, prednimustine (Leo 1031).
    Beckley S; Wajsman LZ; Slack NH; Murphy GP
    Urology; 1981 May; 17(5):446-8. PubMed ID: 7015669
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Estimation of chlorambucil, phenyl acetic mustard and prednimustine in human plasma by high-performance liquid chromatography.
    Newell DR; Hart LI; Harrap KR
    J Chromatogr; 1979 Sep; 164(1):114-9. PubMed ID: 541393
    [No Abstract]   [Full Text] [Related]  

  • 28. Phase II trial of Prednimustine. Leo-1031 (NSC-134087) in acute non-lymphocytic leukemia.
    Juul K; Sørensen P; Pedersen-Bjergaard J; Jensen MK
    Scand J Haematol; 1979 Nov; 23(5):388-92. PubMed ID: 396664
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics of chlorambucil-tertiary butyl ester, a lipophilic chlorambucil derivative that achieves and maintains high concentrations in brain.
    Greig NH; Daly EM; Sweeney DJ; Rapoport SI
    Cancer Chemother Pharmacol; 1990; 25(5):320-5. PubMed ID: 2306791
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase II study of prednimustine in acute non-lymphocytic leukemia, smouldering leukemia, and refractory anemia with excess blasts.
    Gandara DR; Ries CA; Schiff SA; George CB; Lewis JP; Koretz MM; Carter SK
    Cancer Chemother Pharmacol; 1982; 9(1):10-2. PubMed ID: 7139848
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The use of estramustine and prednimustine versus prednimustine alone in advanced metastatic prostatic cancer patients who have received prior irradiation.
    Murphy GP; Gibbons RP; Johnson DE; Prout GR; Schmidt JD; Soloway MS; Loening SA; Chu TM; Gaeta JF; Saroff J; Wajsman Z; Slack N; Scott WW
    J Urol; 1979 Jun; 121(6):763-5. PubMed ID: 458947
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Disposition of orally administered 14C-prednimustine in cancer patients.
    Gaver RC; Deeb G; Pittman KA; Issell BF; Mittelman A; Smyth RD
    Cancer Chemother Pharmacol; 1983; 11(3):139-43. PubMed ID: 6640823
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of the cytotoxic effect of prednimustine in cultured cells with high or low levels of metallothionein.
    Endresen L
    Acta Pharmacol Toxicol (Copenh); 1984 Jan; 54(1):49-57. PubMed ID: 6702467
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase II trial of prednimustine (NSC-134087) in the treatment of small-cell anaplastic carcinoma of the lung.
    Jensen HS; Hansen HH; Dombernowsky P
    Cancer Chemother Pharmacol; 1980; 4(4):259-61. PubMed ID: 6254684
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preliminary clinical study of prednimustine in lung cancer.
    Catane H; Catane R; Takita H; Kaufman JH; Mittelman A; Murphy GP
    J Med; 1977; 8(2):115-21. PubMed ID: 268397
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination of oral idarubicin and prednimustine in advanced breast cancer: a phase II study.
    Barnadas A; Mendiola C; Casado A; Villar A; Jimeno J; Clerigue M; Rosell R; Diaz-Rubio E; Cortés-Funes H; García de Paredes M
    Eur J Cancer; 1997 Feb; 33(2):312-5. PubMed ID: 9135508
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prednimustine (NSC-134087, Leo 1031) treatment of lymphocytic and lymphocytic-histiocytic lymphomas.
    Mattsson W; von Eyben F; Turesson I; Wählby S
    Cancer; 1978 Jan; 41(1):112-6. PubMed ID: 342081
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Premarin priming before prednimustine, high-dose folinic acid and 5-fluorouracil as salvage chemotherapy for advanced breast cancer.
    Marini G; Simoncini E; Marpicati P; Montini E; Ferrari V; Arcangeli G; Zaniboni A
    Chemioterapia; 1988 Apr; 7(2):130-2. PubMed ID: 2840216
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II trial of prednimustine as first-line chemotherapy in patients with advanced breast cancer.
    Rankin EM; Harvey C; Knight RK; Rubens RD
    Cancer Treat Rep; 1987 Nov; 71(11):1107-8. PubMed ID: 3119205
    [No Abstract]   [Full Text] [Related]  

  • 40. Comparative brain and plasma pharmacokinetics and anticancer activities of chlorambucil and melphalan in the rat.
    Greig NH; Sweeney DJ; Rapoport SI
    Cancer Chemother Pharmacol; 1988; 21(1):1-8. PubMed ID: 3342460
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.